Sfoglia per AUTORE
SU WC
Collezione AOU San Luigi di Orbassano

  

Items : 3

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. in JTO clinical and research reports / JTO Clin Res Rep. 2020 Oct 26;2(2):100114. doi: 10.1016/j.jtocrr.2020.100114. eCollection 2021 Feb.
2021
AOU San Luigi di Orbassano

Su WC; Lee JS; Smit EF; Novello S; Kim YC; Reckamp KL; Yang JC; Wakelee H; Popat S; Despain D; Shih D; Golsorkhi T; Hsia TC; Chiari R; Carcereny Costa E; Bazhenova L; Groen HJM; Blakely CM; Su WC; Akerley WL; Lee JS; Smit EF; Novello S; Reckamp KL; Kim YC; Yang JC; Akerley WL; Blakely CM; Groen HJM; et alii...

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1?Positive, Advanced Non?Small-Cell Lung Cancer in the KEYNOTE-010 Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 May 10;38(14):1580-1590. doi: 10.1200/JCO.19.02446. Epub 2020 Feb 20.
2020
AOU San Luigi di Orbassano

Herbst RS; Garon EB; Kim DW; Cho BC; Perez-Gracia JL; Han JY; Arvis CD; Majem M; Forster MD; Monnet I; Novello S; Szalai Z; Gubens MA; Su WC; Ceresoli GL; Samkari A; Jensen EH; Lubiniecki GM; Baas P;

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. in Investigational new drugs / Invest New Drugs. 2016 Oct;34(5):625-35. doi: 10.1007/s10637-016-0368-1. Epub 2016 Jun 27.
2016
AOU San Luigi di Orbassano

Scagliotti G; Kang JH; Smith D; Rosenberg R; Park K; Kim SW; Su WC; Boyd TE; Richards DA; Novello S; Hynes SM; Myrand SP; Lin J; Smyth EN; Wijayawardana S; Lin AB; Pinder-Schenck M;